LLMs demonstrated high accuracy in matching brand and generic names (GPT-4o: 97.38% for brand, 94.71% for generic, P < .01). However, they showed significant inconsistencies in word association tasks.

There were 262,063.05 new cases, 2,742,285.75 prevalence, 115,973.98 deaths, and 2,260,975.34 DALYs of breast cancer among older adults in 2021 in Asia. From 1990 to 2021, the ASRs of breast cancer ...

Of 320 eligible patients approached between January 2021 and July 2022, 239 patients completed the QuIC questionnaires after informed consent discussion for biomarker (n = 128) or therapeutic (n = 111 ...

As a cancer of the immune system, lymphoma exhibits clinical features and treatment strategies that differ markedly from those of solid tumors. Lymphoma uniquely exhibits a bimodal age distribution, ...

JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Pancreatic cancer is soon to be the second leading cause of cancer-related death in the United States. 1 Despite this reality, it is undeniable that there have been improvements in the management of ...

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three ...

Combination therapies demonstrated enhanced benefit over single-agent immunotherapies. A decade later, combination immunotherapy with ipilimumab/nivolumab 4, 5 and relatlimab, an antilymphocyte ...

This is a single-arm, Simon 2-stage trial. Patients with synovial sarcomas who had progressed on at least two lines were administered daily regorafenib (80/120 mg alternating once daily per orally).

We herein report on 60 newly diagnosed IC-ineligible patients treated at our institution with triplet regimens for isocitrate dehydrogenase (IDH)–mutant AML. Patients received either AZA + VEN + IVO ...